INTRODUCTION
A denosine is an immunomodulator with anti-inflammatory properties, such as the promotion of endothelial barrier function (Lennon et al., 1998) and the regulation of cytokine production by macrophages (Bouma et al., 1994; Hasko et al., 1996) , superoxide production by neutrophils (Cronstein et al., 1986) , and mediator release by mast cells (Ramkumar et al., 1993) . The effects of adenosine are mediated by seven-transmembranespanning G-protein-coupled adenosine receptors that modulate intracellular cAMP levels.
CD73 is a widely distributed membrane-bound glycosyl phosphatidylinositol (GPI)-anchored protein (Frick and Lowenstein, 1978; Darvish et al., 1996) . It is involved in transmitting activation signals to Tcells (Thompson et al., 1989) , binding to fibronectin and laminin (Stochaj et al., 1989) , and the adhesion of lymphocytes to endothelial cells Arvilommi et al., 1997) . CD73 catalyzes the dephosphorylation of AMP and other nucleoside monophosphates and is a dominant contributor to the generation of extracellular adenosine (Zimmermann, 1992) . Adenosine can be metabolized by two enzymes, adenosine deaminase and adenosine kinase. While adenosine kinase rephosphorylates adenosine to AMP, adenosine deaminase deaminates adenosine to inosine, the first step in its conversion to uric acid. Adenosine deaminase is distributed in virtually all human tissues and is expressed in the lymphoid system at high levels.
Although adenosine deaminase is found mainly in the cytoplasm, in humans it also appears on the cell surface as an ecto-enzyme, anchored to CD26 (Kameoka et al., 1993) .
We previously demonstrated that CD73 is responsible for the formation of extracellular adenosine (Hashikawa et al., 2003) . Since adenosine is rapidly metabolized, it is likely that adenosine generated from 5Ј-AMP by CD73 can subsequently interact only with adenosine receptors proximal to CD73 (Matsuoka et al., 2002; Hashikawa et al., 2003) . Interestingly, membrane-bound adenosine deaminase might also be located close to adenosine receptors (Hashikawa et al., 2004) . If so, this would further confine adenosine receptor activation to the microenvironmental site of adenosine generation through CD73. However, the role of ecto-adenosine deaminase in regulating the extracellular concentration of adenosine and subsequent adenosine receptor activation, and especially in adenosine receptor activation mediated by CD73-generated adenosine, remains to be clarified. In this study, to clarify the mechanisms by which adenosine action is regulated, we investigated the expression of CD26 and ectoadenosine deaminase in human gingival fibroblasts, and the involvement of ecto-adenosine deaminase in CD73-dependent adenosine receptor stimulation.
ABSTRACT
CD73 (ecto-5Ј-nucleotidase) on human gingival fibroblasts plays a role in the regulation of intracellular cAMP levels through the generation of adenosine, which subsequently activates adenosine receptors. In this study, we examined the involvement of ecto-adenosine deaminase, which can be anchored to CD26 on human gingival fibroblasts, in metabolizing adenosine generated by CD73, and thus attenuating adenosine receptor activation. Ecto-adenosine deaminase expression on fibroblasts could be increased by pre-treatment with a lysate of Jurkat cells, a cell line rich in cytoplasmic adenosine deaminase. Interestingly, the cAMP response to adenosine generated from 5Ј-AMP via CD73 and the ability of 5Ј-AMP to induce hyaluronan synthase 1 mRNA were significantly decreased by the pre-treatment of fibroblasts with Jurkat cell lysate. This inhibitory effect was reversed by the specific adenosine deaminase inhibitor. These results suggest that ecto-adenosine deaminase metabolizes CD73-generated adenosine and regulates adenosine receptor activation.
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Human Gingival Fibroblasts
All human subjects participating in this study provided informed consent to a protocol that was reviewed and approved by the Institutional Review Board of the Osaka University Graduate School of Dentistry. Human gingival fibroblasts obtained from biopsies of healthy gingiva from six healthy volunteers (four males and two females, from 12 to 18 yrs old) were explanted into ␣-modified Eagle's medium (␣-MEM, Nikken Biomedical Laboratory, Kyoto, Japan) supplemented with 300 g/mL kanamycin sulfate and 2.5 g/mL fungizone, and then cultured with ␣-MEM supplemented with 10% fetal calf serum (FCS, JRH Biosciences, Lenexa, KS, USA) at 37°C in a humidified atmosphere of 5% CO 2 /95% air. The cells detached from the explants with 0.05% trypsin-0.02% EDTA (Life Technologies, Grand Island, NY, USA) in PBS (Nikken Biomedical laboratory) were subcultured in plastic flasks (Corning, Corning, NY, USA). Fibroblasts were passaged after trypsinization and used for experiments at passages 4-10.
Preparation of Jurkat Lysate as a Source of Adenosine Deaminase
Jurkat cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and maintained in RPMI-1640 (Nikken Biomedical laboratory) supplemented with 10% FCS and 60 g/mL kanamycin sulfate. Logarithmically grown Jurkat cells were collected by centrifugation, re-suspended in culture medium at a concentration of 1 x 10 8 /mL, and subject to lysis by being frozen and thawed 3 times. Debris was removed by centrifugation (15,000 rpm in a microfuge for 10 min). The enzyme activity of adenosine deaminase from the Jurkat lysate was 219 mols/hr/mL.
To increase ecto-adenosine deaminase expression in fibroblasts, we incubated fibroblasts in 100 L of the above-mentioned Jurkat lysate for 30 min at 37°C, and then washed them twice before further experiments.
Flow Cytometric Analysis
Cell-surface antigens were detected by flow cytometry with a Becton-Dickinson FACSCalibur. Cells were stained as previously described (Murakami et al., 1993) , with an isotype-matched murine myeloma protein (Mouse IgG 1 , MOPC-21) or normal goat IgG as controls. The following antibodies were used: PE-antihuman CD26 (Pharmingen, San Diego, CA, USA), goat antiadenosine deaminase (Hashikawa et al., 2004) , and FITC-donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Data were collected on 10,000 cells for single-color staining and were analyzed with CellQuest software (Becton Dickinson, Mountain View, CA, USA).
Measurements of Cyclic Adenosine Monophosphate (cAMP) Responses
Monolayers of fibroblasts grown to confluence in six-well plates (Corning) were washed twice with HBSS. Cells were pre-incubated for 10 min at 37°C in the medium containing the cAMP phosphodiesterase inhibitor, 4-(3-butoxy-4-methoxy-benzyl)
imidazolidin-2-one, at 10 M. Cells were then incubated in the same plates for 5 min at 37°C in 5% CO 2 with the following reagents: media alone, and adenosine (20 M) or AMP (20 M), with or without dCF (5 M). Each of the doses induced an unsaturated cAMP response and hyaluronan synthase 1 mRNA expression. cAMP levels were determined with the use of a cAMP enzyme immunoassay (EIA) kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) according to the manufacturer's instructions. All assays were performed in duplicate with 50 L of cell extracts. cAMP levels in unstimulated cells were subtracted from the values recorded.
Detection of Hyaluronan Synthase 1-3 (HAS1, HAS2, and HAS3) mRNAs by RT-PCR
Total RNA was isolated from fibroblasts with an RNA-Bee kit (TEL-TEST, Inc., Friendswood, TX, USA) according to the manufacturer's instructions. The precipitated RNA was resuspended in 0.1% diethylpyrocarbonate-treated distilled water. cDNA was synthesized and amplified via PCR as described previously (Murakami et al., 2001) . Oligonucleotide PCR primers specific for hyaluronan synthase (HAS) 1, 2, 3, and HPRT mRNA were synthesized by Clontech (Palo Alto, CA, USA). The primer sequences were as follows: HPRT (hypoxanthine phosphoribosyl transferase), 5Ј-CGAGATGTGATGAAGGAGATGGG-3Ј (forward), 5Ј-GCCTGACCAAGGAAAGCAAAGTC-3Ј (reverse); HAS1, 5Ј-TGCGATACTGGGTAGCCTTCAATG-3Ј (forward), 5Ј-CGTTGTACAGCCACTCACGGAAGTA-3Ј (reverse); HAS2, 5Ј-TCTGGGAATGTACAGAAACTC-3Ј (forward), 5Ј-AGACATGAAGACCATGACGAT-3Ј (reverse); and HAS3, 5Ј-TTGGGCATGTACCGCAACA-3Ј (forward), 5Ј-GGGACATG AAGATCATCTCTGC-3Ј (reverse). The density of each band in the agarose gels was quantified with the use of Quantity One software (BIO-RAD Laboratories, Inc., Hercules, CA, USA).
Statistical Analysis
Statistical analyses of the results were performed by one-way ANOVA and Fisher's PLSD tests.
RESULTS

Surface Expression of Ecto-adenosine Deaminase on Human Gingival Fibroblasts
Since adenosine deaminase can localize on the cell surface through its interaction with CD26 (Kameoka et al., 1993; Hashikawa et al., 2004) , the expression of ecto-adenosine deaminase and CD26 on fibroblasts was examined. Little expression of ecto-adenosine deaminase was observed on in vitro-maintained fibroblasts (Fig. 1A) , although the expression of CD26 was detected constitutively (Fig. 1B) . Fibroblasts were then treated with Jurkat cell lysate as a source of exogenous adenosine deaminase (Hashikawa et al., 2004) . As expected, treatment with Jurkat lysate resulted in an increase in the expression of ecto-adenosine deaminase on the fibroblasts (Fig. 1A) .
Regulation of cAMP Responses to Adenosine by Ecto-adenosine Deaminase
We then investigated the regulation of adenosine receptor (AdoR) engagement by ecto-adenosine deaminase on fibroblasts. We first maximized ecto-adenosine deaminase levels on fibroblasts by saturating CD26 with ecto-adenosine deaminase through preincubation of fibroblasts with Jurkat cell lysate. Then, we examined the adenosine-induced cAMP responses in the pre-incubated fibroblasts in the presence or absence of dCF. The adenosineinduced cAMP response was significantly inhibited (39%) by Jurkat cell lysate treatment, and the inhibitory effect was reversed by the addition of dCF ( Fig. 2A) . In the presence of dCF, the cAMP response to adenosine after cell lysate treatment was higher than that without lysate treatment ( Fig. 2A ).
Regulation of HAS 1 mRNA Expression by Ecto-adenosine Deaminase
Production of extracellular matrices is an important function of human gingival fibroblasts. Among the extracellular matrices, hyaluronan (HA) plays multifunctional roles in the growth and differentiation of cells during the course of inflammatory reactions and the process of wound-healing and regeneration in periodontal tissues (Shimabukuro et al., 2005) . We previously reported that adenosine enhanced HAS mRNA expression in HGF, and that the expression was markedly abrogated by the AdoR antagonist XAC (Murakami et al., 2001) . This also indicates that intracellular signaling via AdoR can be monitored by HAS mRNA expression in gingival fibroblasts. Of the three different isoforms of HAS (HAS1, HAS2, and HAS3), we found that HAS1 mRNA was specifically induced by adenosine treatment of fibroblasts (Fig. 2B) . In contrast, adenosine treatment did not affect the expression of either HAS2 or HAS3 mRNA (Fig. 2B) . To evaluate further the ability of ecto-adenosine deaminase to regulate AdoR engagement, we examined the influence of dCF on adenosineinduced HAS1 mRNA expression by fibroblasts. Fibroblasts pre-incubated with or without Jurkat cell lysate were examined for adenosine-induced HAS1 mRNA expression in the presence and absence of dCF, by RT-PCR. Pre-treatment with Jurkat cell lysate decreased not only adenosine-induced cAMP ( Fig. 2A) , but also HAS1 mRNA expression (Fig. 2C) , and the effect of the pre-treatment was also reversed by the addition of dCF (Fig. 2C) . The fact that the intensity of HAS1 mRNA expression with dCF was unaffected by Jurkat lysate treatment indicates that the increase in HAS1 mRNA expression was not caused by dCF alone.
Regulation of cAMP Response and HAS1 mRNA Expression in Human Gingival Fibroblasts by Ecto-adenosine Deaminase and CD73
We recently found that CD73 is expressed in fibroblasts and is involved in the production of adenosine (Hashikawa et al., 2003) . Our next question was whether ecto-adenosine deaminase could regulate the interaction of adenosine generated from AMP via CD73, with AdoRs. Fibroblasts preincubated with or without Jurkat lysate were examined for AMP-induced cAMP responses in the presence or absence of dCF. Interestingly, pre-treatment with Jurkat lysate significantly inhibited the cAMP response (27%), and the inhibitory effect was reversed by the addition of dCF (Fig. 3) . To investigate further the regulation of AdoR engagement by ecto-adenosine deaminase and CD73, we examined AMPinduced HAS1 mRNA expression in fibroblasts. Treatment with 5Ј-AMP also increased HAS1 mRNA expression in fibroblasts (Fig. 4A) , and the increase was completely inhibited by the AdoR antagonist, XAC (Fig. 4A ). Furthermore, pretreatment of fibroblasts with Jurkat cell lysate decreased AMPinduced HAS1 mRNA expression (Fig. 4B) , and the effect of the pre-treatment was reversed by dCF ( Fig. 4B) , consistent with the findings shown in Fig. 3 .
DISCUSSION
In this study, we first clarified the involvement of fibroblast ecto-adenosine deaminase, which is likely anchored on CD26, in regulating AdoR engagement by extracellular adenosine, in CD73-dependent adenosine receptor stimulation.
Adenosine deaminase is found mainly in the cytosol, but it has been shown to be anchored to CD26 on cell surfaces as well (Aran et al., 1991; Darvish et al., 1996) . Pre-treatment of fibroblasts with an exogenous source of adenosine deaminase, a cell lysate of Jurkat, which includes abundant cytosolic adenosine deaminase, resulted in an increase in ecto-adenosine deaminase expression. Although this increase in ecto-adenosine deaminase expression on fibroblasts led to some metabolism of extracellular adenosine added to the culture medium, the reduction in adenosine concentration was not statistically significant (data not shown). In contrast, pre-treatment of fibroblasts with Jurkat cell lysate led to a significant suppression of adenosine-induced cAMP and HAS1 mRNA responses. These decreases were abrogated by dCF. These results are consistent with our findings with CD26-transfected lymphoid cells and recombinant adenosine deaminase (Hashikawa et al., 2004) . Our previous findings suggested that although adenosine deaminase anchored on the cell surface of fibroblasts cannot markedly diminish overall extracellular adenosine levels in culture media (data not shown), it can regulate local concentrations of adenosine in the vicinity of AdoRs and, consequently, AdoR activation. Since a high concentration of adenosine can be cytotoxic, this microenvironmental regulation of adenosine concentration is extremely beneficial to cells and tissues. It is likely that lysed cells in inflammatory lesions can be a source of adenosine deaminase, which subsequently binds to CD26. In addition, CD26 expression on fibroblasts can be induced by inflammatory cytokines such as IL-1␤, leading to an increased capacity for adenosine deaminase binding (data not shown).
In contrast, CD73 (ecto-5Ј-nucleotidase) on fibroblasts contributes to the generation of adenosine and, in turn, the activation of adenosine receptors (Hashikawa et al., 2003) . Thus, both CD73 and ecto-adenosine deaminase on fibroblasts play key roles in the regulation of the adenosine concentration in the vicinity of AdoR and subsequent adenosine receptor activation. Furthermore, the expression level of CD73 and its enzymatic activity are also modulated by several inflammatory mediators, such as IL-1␤ (Savic et al., 1990) , NO (Obata et al., 1998) , PGE 2 (Savic et al., 1991) , and TNF␣ (Savic et al., 1990; Kalsi et al., 2002) . Thus, the regulation of AdoR activation by CD73 and CD26-anchored adenosine deaminase on fibroblasts can be modulated by various mediators in inflamed periodontal lesions.
The anti-inflammatory effects of adenosine are welldocumented (Cronstein, 1994; Ohta and Sitkovsky, 2001) . We recently found, by RT-PCR, that both CD73 and adenosine deaminase gene expression are enhanced in inflamed human gingival tissues, compared with control healthy gingival tissues (data not shown), although the specific cells expressing CD73 and adenosine deaminase, and the mechanisms by which the expression of these molecules is modulated in inflamed tissue, remain to be clarified. Our findings suggest that the enzymatic activities of both molecules should be increased in periodontitis lesions. Thus, enhancing the biological effects of adenosine at inflamed sites, possibly by an activator of CD73 or an inhibitor of adenosine deaminase, might be a new therapeutic approach to periodontitis. Further studies will be required to address the molecular mechanisms by which adenosine regulates inflammatory reactions in periodontitis.
